Additional file 1: of Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance

Online supplemental material - PICO tables and GRADE tables produced for each scoping question. (DOCX 169 kb

Psychotropics in the next edition of the Interagency Emergency Health Kit [1].

a<p>The three anti-convulsants are phenobarbital (1,000 50-mg tablets), diazepam (200 injections, 5 mg/ml; 2 ml/ampoule), and magnesium sulfate (40 injections; 500 mg/ml; 10 ml/ampoule).</p>b<p>The five psychotherapeutic medicines are amitriptyline (4,000 25-mg tablets); biperiden (400 2-mg tablets), diazepam (240 5-mg tablets), haloperidol (1,300 5-mg tablets), and haloperidol (20 injections; 5 mg/ml; 1 ml/ampoule).</p

The WHO Model List of Essential Medicines and the Interagency Emergency Health Kit (IEHK).

a<p>Indicates that the medicine represents a pharmacological class (similar clinical performance).</p

Advantages and disadvantages of including fluoxetine versus amitriptyline in the Interagency Emergency Health Kit (IEHK).

<p>Advantages and disadvantages of including fluoxetine versus amitriptyline in the Interagency Emergency Health Kit (IEHK).</p

(A): Representative saturation binding experiments which show the total bound, non-specific bound and specific bound

<p><b>Copyright information:</b></p><p>Taken from "Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy"</p><p>http://www.molecular-cancer.com/content/6/1/48</p><p>Molecular Cancer 2007;6():48-48.</p><p>Published online 15 Jul 2007</p><p>PMCID:PMC1939854.</p><p></p> (B): Representative Scatchard plots which were used to determine and values

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy-5

<p><b>Copyright information:</b></p><p>Taken from "Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy"</p><p>http://www.molecular-cancer.com/content/6/1/48</p><p>Molecular Cancer 2007;6():48-48.</p><p>Published online 15 Jul 2007</p><p>PMCID:PMC1939854.</p><p></p> or 1 mg/day n = 10; dashed line) or vehicle control (20% DMSO n = 10; solid line). Mice treated with WC26 had smaller tumors compared to animals vehicle control (p < 0.0001). The two treatment groups were not statistically different. The double-headed arrow denotes the treatment period (5 days). Survival of mice treated with WC26 compared favorably to the mice treated vehicle control (p= 0.002). Survival endpoints were defined as tumor diameter >15 mm or tumor ulceration

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy-0

<p><b>Copyright information:</b></p><p>Taken from "Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy"</p><p>http://www.molecular-cancer.com/content/6/1/48</p><p>Molecular Cancer 2007;6():48-48.</p><p>Published online 15 Jul 2007</p><p>PMCID:PMC1939854.</p><p></p>d. Panel C: Sigma-2 receptor-specific ligands SV119 and WC26. Panel D: Chemically-labeled sigma-2 receptor-specific ligands K05-138 (fluorescein-labeled), RHM-1 (H-labeled), and RHM-4 (F-labeled)

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy-7

<p><b>Copyright information:</b></p><p>Taken from "Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy"</p><p>http://www.molecular-cancer.com/content/6/1/48</p><p>Molecular Cancer 2007;6():48-48.</p><p>Published online 15 Jul 2007</p><p>PMCID:PMC1939854.</p><p></p>ng mice). Single cell suspensions were incubated for 1 hour with KO5-138 (a fluorescent labeled sigma-2 receptor ligand, at 50 nM (thin doted line) or 100 nM (thick solid line) of ligand, or left unstained (thin solid line). FACS histograms demonstrate 100 fold more florescence in tumors compared to normal tissues. : Human pancreatic cancer lines (CFPAC-1, Panc-1, AsPC-1) demonstrate similar high degree of sigma-2 ligand binding to when compared to our murine model (Panc-02). Fluorescein signal peaks were shown in unstained control (thin solid line), 50 nM of ligand (dotted line), or 100 nM of ligand (thick solid line). The experiment was repeated twice with identical results. : Representative Micro PET/CT images of pancreas adenocarcinoma (Panc-02) bearing C57BL/6 mice administered RHM-4 (F-labled sigma-2 ligand). The tumor indicated by arrows was approximately 1 cm. The additional hot spot represents metastatic tumor in a regional lymph node

Systemic administration of the sigma-2 receptor ligand WC26 induces considerable apoptosis in Panc-02 tumor allografts (up to 50% of tumor cells were active caspase-3 positive following a single 2 mg dose of WC26, p 0

<p><b>Copyright information:</b></p><p>Taken from "Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy"</p><p>http://www.molecular-cancer.com/content/6/1/48</p><p>Molecular Cancer 2007;6():48-48.</p><p>Published online 15 Jul 2007</p><p>PMCID:PMC1939854.</p><p></p>0001). Data reported as percent specific apoptosis (percent specific apoptosis = observed apoptosis – tissue specific background apoptosis). The mice appeared normal and no apparent toxicity was noted in serum biochemical analysis or by immunohistochemistry (data not shown). Reference ranges for the blood chemistry panel in C57Bl/6 mice: ALT: 18–184 U/L, AST: 55–251 U/L, glucose: 174–335 mg/dL, amylase: 2595 +/- 212 U/L, BUN: 34–58 mg/dL, creatinine < 1.1 mg/dL

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy-6

<p><b>Copyright information:</b></p><p>Taken from "Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy"</p><p>http://www.molecular-cancer.com/content/6/1/48</p><p>Molecular Cancer 2007;6():48-48.</p><p>Published online 15 Jul 2007</p><p>PMCID:PMC1939854.</p><p></p>d. Panel C: Sigma-2 receptor-specific ligands SV119 and WC26. Panel D: Chemically-labeled sigma-2 receptor-specific ligands K05-138 (fluorescein-labeled), RHM-1 (H-labeled), and RHM-4 (F-labeled)